Deuruxolitinib (Leqselvi) for Severe Alopecia Areata
Deuruxolitinib (Leqselvi) for Severe Alopecia Areata
October 27, 2025 (Issue: 1740)
The FDA has approved the oral Janus kinase (JAK)
inhibitor deuruxolitinib (Leqselvi – Sun) for treatment
of severe alopecia areata in adults. Two other oral
JAK inhibitors are approved for treatment of severe
alopecia areata: baricitinib...more
- Baricitinib (Olumiant) for severe alopecia areata. Med Lett Drugs Ther 2022; 64:139.
- Ritlecitinib (Litfulo) for severe alopecia areata. Med Lett Drugs Ther 2023; 65:185.
- S Lee et al. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol 2018; 154:1145. doi:10.1001/jamadermatol.2018.2312
- N Meah et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol 2020; 83:123. doi:10.1016/j.jaad.2020.03.004
- B King et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386:1687. doi:10.1056/nejmoa2110343
- B King et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 2023; 401:1518. doi:10.1016/s0140-6736(23)00222-2
- B King et al. Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: week 152 data from BRAVE-AA2. J Am Acad Dermatol 2025; 92:299. doi:10.1016/j.jaad.2024.09.072
- C Tziotzios et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol 2025; 39:1152. doi:10.1111/jdv.20526
- BA King and BG Craiglow. Janus kinase inhibitors for alopecia areata. J Am Acad Dermatol 2023; 89:S29. doi:10.1016/j.jaad.2023.05.049
- B King et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol 2024; 91:880. doi:10.1016/j.jaad.2024.06.097
- B King. Results from THRIVE-AA2: a double blind, placebo-controlled phase 3 clinical trial of deuruxolitinib (CTP-543), an oral JAK inhibitor, in adult patients with moderate to severe alopecia areata. American Academy of Dermatology 2023 Annual Meeting; New Orleans, LA; March 17-21, 2023. Available at: https://bit.ly/488NmZ7. Accessed October 8, 2025.
- FDA Center for Drug Evaluation and Research. Multi-discipline review. Deuruxolitinib. July 24, 2024. Available at: https://bit.ly/4m2ioFp. Accessed October 8, 2025.
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Deuruxolitinib. [Updated 2024 Aug 15]. Available at: https://bit.ly/4mWbuC6. Accessed October 8, 2025.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Deuruxolitinib (Leqselvi) for Severe Alopecia Areata
Article code: 1740b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
